In the United States, the rising use of GLP-1 receptor agonists for obesity management is contributing to declining bariatric surgery rates, according to recent studies and healthcare reports. Medications such as semaglutide and tirzepatide have gained significant popularity because of their substantial weight-loss benefits and non-invasive treatment approach. Researchers noted that bariatric surgery volumes have declined by more than 20% in recent years as increasing numbers of patients opt for pharmacological therapy before considering surgery.
However, experts emphasized that bariatric surgery continues to provide the most durable long-term weight-loss outcomes, particularly in patients with severe obesity and obesity-related comorbidities. Studies also suggest that bariatric surgery may become more cost-effective than long-term GLP-1 therapy over time. Specialists highlighted that…
